Lenzetto

Estradiol Hemihydrate, the active ingredient in Lenzetto, is an estrogen presented as a transdermal patch for transdermal use. It treats moderate to severe menopausal vasomotor symptoms, helps prevent osteoporosis in postmenopausal women, and addresses hypoestrogenism caused by ovarian failure or hypogonadism. GNH USA supplies Lenzetto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lenzetto, an estrogen therapy, is indicated for several menopause‑related and hypoestrogenic conditions.

- Menopausal vasomotor symptoms: relief of moderate to severe hot flashes and night sweats. - Postmenopausal osteoporosis: prevention of bone loss and reduction of fracture risk. - Hypoestrogenism due to ovarian failure: restoration of estrogen levels in women with ovarian insufficiency. - Hypogonadism: treatment of estrogen deficiency in women with hypogonadal states.

Lenzetto may cause adverse reactions typical of systemic estrogen exposure.

Common Side Effects: - Skin irritation at patch site: redness, itching, or rash. - Nausea: mild to moderate stomach upset. - Breast tenderness: swelling or discomfort. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Stroke: cerebrovascular accident. - Endometrial hyperplasia or carcinoma: abnormal uterine bleeding.

Before prescribing Lenzetto, clinicians should evaluate individual risk factors and monitor patients regularly. - Cardiovascular risk: assess history of thromboembolic events before use. - Breast cancer: avoid in women with active or past estrogen‑dependent breast cancer. - Liver disease: use with caution in severe hepatic impairment. - Pregnancy and lactation: contraindicated; avoid in pregnant or breastfeeding women. - Store at room temperature below 25°C: keep in original pouch, protect from moisture and light.

Estradiol can interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Oral anticoagulants (warfarin): may increase clotting risk. - Strong CYP3A4 inhibitors (ketoconazole, itraconazole): can raise estradiol plasma levels. - Hormonal contraceptives: additive estrogen effect may increase thrombotic risk.

Moderate Interactions (Monitor Closely): - Antihypertensives: estrogen may reduce blood‑pressure control. - Thyroid hormones: may alter thyroid‑binding globulin and hormone levels. - Antidepressants (SSRIs): may affect hot‑flash control and estrogen metabolism.